Biogen Inc. (BIIB) Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB). Investors who purchased Biogen Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BIIB.

Investigation Details:

On February 14, 2024, Biogen disclosed receipt of a subpoena from the U.S. Department of Justice seeking information about its “business operations in several foreign countries.” On this news, Biogen's stock price fell $5.91 per share, or 2.6%, to close at $220.74 per share on February 14, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Biogen Inc. securities, you can assist this investigation by visiting the firm’s site: bgandg.com/BIIB. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240314122094/en/

The Biogen Stock at the time of publication of the news with a fall of -3,11 % to 219,5USD on Nasdaq stock exchange (14. März 2024, 22:59 Uhr).